SGLT2 Inhibitors in Diabetic Kidney Disease

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Canagliflozin in Patients with Baseline eGFR

(2020) George Bakris et al.   Clinical Journal of the American Society of Nephrology

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.

(2020) Megumi Oshima et al.   KIDNEY INTERNATIONAL

Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

(2020) Bettina J. Kraus et al.   KIDNEY INTERNATIONAL

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Appraisal of Non-Cardiovascular Safety for Sodium–Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials

(2019) Fang-Hong Shi et al.   Frontiers in Pharmacology

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

(2019) Brendon L Neuen et al.   Lancet Diabetes & Endocrinology

Gaps and barriers in health-care provision for co-morbid diabetes and chronic kidney disease: a cross-sectional study

(2017) C. Lo et al.   BMC Nephrology